Understanding how to reprogram adult cells to the pluripotent state opens up new horizons in human biology, provides new tools to study disease, and indicates the route to future personalized stem cell therapy. The research by John Gurdon of the Gurdon Institute, Cambridge, UK and Shinya Yamanaka of Kyoto University, Japan that has led to successful reprogramming of adult cells to the pluripotent state earns them this year's Albert Lasker Basic Medical Research Award. The contributions of the two awardees are very different in kind and in timelines, but together they have changed the way we think about the stability of the differentiated cell state. John Gurdon is recognized for his lifelong endeavor to understand the process by which an adult cell nucleus can be reprogrammed to start development all over again when transplanted into an egg. Shinya Yamanaka, on the other hand, has leapt into prominence in very short order, with a series of experiments beginning in 2006 showing that adult cells can be reprogrammed to pluripotency directly by added expression of just four key transcription factors, generating so-called induced pluripotent stem (iPS) cells. The joint award is a satisfying way of recognizing that every new breakthrough depends on the cumulative knowledge generated over years of research-"standing on the shoulders of giants."
The discoveries of nuclear transfer reprogramming by Gurdon and induced pluripotent stem cells by Yamanaka both challenged the underlying paradigms of developmental biology in important ways and so were of immediate impact in the scientific community. But both discoveries also took place in the glare of the media because of their association with the controversial issues of cloning and the derivation of pluripotent cells from human embryos. Indeed, Yamanaka's discovery of iPS cells, apart from being great science, has been remarkable for the way in which it has transformed the public debate on the ethics of stem cell research. Although the media and the public may continue to focus on the ethical controversies, the Lasker prize and this Essay focus on the importance of the underlying science, which is of the highest order.
From Frogs to Dolly
John Gurdon is one of the major figures in modern vertebrate developmental biology, whose scientific contributions, scholarly works, and science leadership have inspired the careers of many (including the author of this Essay) and shaped our understanding of early embryo development and gene regulation. Famously, Gurdon was not considered a strong science student in school. His report card at Eton read: "I believe Gurdon has ideas about becoming a scientist: on his present showing this is quite ridiculous: if he can't learn simple biological facts …. it would be a sheer waste of time, both on his part and of those who would have to teach him" (Gurdon, 2006) . But when we examine Gurdon's career we see why the teacher was upset. John is driven by curiosity, always asks clear and interesting questions, and strives to make sense of the answers. The kind of science teaching that is still too prevalent in our schools, in which science is considered as a set of facts that need to be learned by rote, is the complete antithesis of Gurdon's approach. A case study of Gurdon's career, in which he always asked apparently simple questions and devised apparently simple experiments to test them, would help our science educators understand how to engage students in the excitement and fun of science discovery.
The simple question that led Gurdon to his major discoveries in nuclear transfer was: "is the genome irreversibly altered as cells become more specialized during development?" In the 1960s, it was already clear that the program of development relied on differential gene expression leading to apparently irreversible specialization of cells. What was unclear was how this stability of the differentiated state could be maintained without underlying changes in the genome. Barbara McClintock had shown that mobile elements could "jump" around the genome and change gene transcription, so could development involve DNA changes that permanently turned genes on or off? Gurdon realized that the best way to test whether the genome was intact in a specialized cell was to take that genome back to the beginning of development and ask whether it retained the capacity to drive normal development. Gurdon extended these early experiments in a series of seminal studies beginning in the late 1950s, using the African clawed toad, Xenopus laevis, which had become and continues to be the amphibian most used in laboratory studies. Using nuclei carrying a ribosomal RNA gene deletion as a marker, he was able to generate live frogs from transplanted neurula stage endoderm (Gurdon, 1962a) . When he moved on to more differentiated cells, the success rate of producing normal development went down considerably. However, differentiated brush border intestinal nuclei from feeding tadpoles could result in fertile adult frogs after nuclear transfer (Gurdon, 1962b) . Gurdon interpreted these rare successes as clear evidence that cell differentiation did not involve permanent changes to the genome, and the many abnormal embryos as representing failures in the correct reprogramming of the nuclei by the cytoplasm of the egg. Naysayers persisted, and Gurdon and colleagues continued to pursue the question of whether a truly differentiated adult cell nucleus could successfully be reprogrammed by the egg cytoplasm. Their most successful experiments in the 1970s showed that adult keratin-expressing skin cells could donate nuclei that would result in feeding tadpole stages of development, after serial nuclear transfer (Gurdon, 2006) .
Even in the early days of nuclear transfer experiments in frogs, journalists rapidly extrapolated from frogs to humans and the ethical furore over human cloning began. Books and movies (e.g., The Boys from Brazil) took science fact and made science fiction. Of course, this media attention was nothing to the media storm in 1996 that accompanied the birth of Dolly the sheep, the first mammal cloned by somatic cell nuclear transfer (SCNT) from an adult cell donor. Since the birth of Dolly, viable nuclear transfer-derived offspring have been made in many different mammalian species, although notably not yet in primates. In mice it has been conclusively shown that a nucleus from a highly specialized cell, such as a lymphocyte or an olfactory epithelial cell, can generate viable cloned offspring. Why did it take so long for success in frogs to translate into success in mammals? Success rates for nuclear transfer in mammals are low, usually no more than 1% to 3% at best and, as with frogs, the success rate rapidly declines when adult nuclei are used instead of early embryonic nuclei. Many groups began experiments but gave up when faced with the formidable numbers of eggs and embryos needed to see success. Probably the reason why the first cloned mammal was a sheep rather than a mouse was because the potential commercial benefit of genetically manipulating domestic animals maintained research interest in a difficult field.
The success of nuclear transfer not only demonstrated nuclear totipotency but also showed that the egg cytoplasm must be able to reshape the epigenetic environment of the nucleus to allow the entire program of development to be reset. John Gurdon has continued through the rest of his career to be fascinated by this problem and, like all good problems, he has been able to return to it at intervals when new tools and techniques arise. While Professor of Embryology at Oxford, he provided early evidence that major changes in chromatin structure are one of the first events that occur. At this time also, he began a series of studies on the behavior of nucleic acid macromolecules when injected into Xenopus eggs or oocytes, in the hope of providing a simpler system to study reprogramming. He showed that DNA could be replicated after injection into eggs and that mRNA was translated after injection into eggs or oocytes-fundamental studies that continue to resonate today. Egg extracts have been used to study DNA replication in vitro, and mRNA injection into oocytes has been used as a "living test-tube" to identify receptors for neurotransmitters, ion channel genes, etc.
Gurdon moved from Oxford to the MRC Laboratory of Molecular Biology in Cambridge in 1971 and became Director of the Wellcome Trust/CRC Institute in 1989. Upon his official retirement as Director, the Institute changed its name to the Gurdon Institute, in his honor. Throughout all of these years Gurdon stayed at the bench and continued to work on the overall changes that occur when nuclei are injected into eggs or oocytes. Recent work from the Gurdon lab has shown that nuclei may retain "epigenetic memory" of their cell of origin for many cell divisions after nuclear transfer, even while the embryonic gene expression program is being activated. All of these experiments have tended to suggest that the process of nuclear reprogramming by the egg is a complex one that is often incomplete, involving general erasure of chromatin marks and gradual reestablishment and replacement of transcription factor hierarchies. Despite the years of studying the process of nuclear transfer, it is still not possible to reconstruct the reprogramming milieu of the egg cytoplasm in vitro.
From Frogs and Dolly to ES Cells and iPS Cells
The first reports of deriving human embryonic stem (ES) cells occurred soon after the reports of successful cloning in mammals, and it was only a short step to link the two. Although live cloned animals are relatively rare, blastocysts derived by SCNT can be used to generate embryonic stem cells in mice (Wakayama et al., 2001) (Figure 1 ). Excitement and controversy accompanied the concept of being able to replicate this result with human cells: excitement because of the future prospects for personalized stem cell therapy and the present opportunities for generating disease-specific stem cells to study disease mechanisms in vitro; controversy because of the possible connection to human reproductive cloning, the ethical issues around oocyte donation, and the deliberate creation and destruction of human embryos, albeit very early ones. However, although primate ES cells derived by SCNT have been reported, no success with human has been reported to date. Even in mouse, the number of oocytes needed to generate successful SCNT ES cell lines is large and the practical difficulties of garnering human oocytes in large numbers have impeded any real progress in this area.
All (Takahashi and Yamanaka, 2006) (Figure 1 ). These initial iPS cells were not completely identical to ES cells and their ability to contribute to tissues in chimeras was limited, with no germline transmission. And the efficiency of production was very low. However, no one before had come even close to this kind of dramatic direct reversal of differentiation. Rapidly thereafter, Yamanaka's lab and others improved the selection process for generating iPS cells and were able to generate cells that could transmit the iPS cell genotype into the next generation (Okita et al., 2007; Wernig et al., 2007) . Continued improvements in mouse iPS cell technology have recently led to the generation of viable mice entirely composed of iPS cells by the tetraploid complementation approach, the final test of iPS cell pluripotency.
Although generation of mouse iPS cells caused a major stir in the research community, it was not until Yamanaka's lab and James Thomson's lab separately reported success in reprogramming adult human skin cells to pluripotency that the world at large took notice. Yamanaka's lab used the same set of transcription factors as used in mice (Takahashi et al., 2007) , whereas Thomson replaced c-MYC and KLF4 with LIN28 and NANOG (Yu et al., 2007) . These human iPS cells were pluripotent as judged by in vitro differentiation, teratoma formation, gene expression, and epigenetic profiles, suggesting that the goal of making patient-specific stem cells could be achieved without resorting to nuclear transfer. Right-to-life groups were quick to suggest that human iPS cell technology made all human ES cell research unnecessary, an assertion that was rapidly countered by Yamanaka himself, who pointed out that human ES cells are still the established standard against which to measure progress in the development of iPS cell methodologies.
So what was the path that led Yamanaka to his discovery and why was it unique? Shinya Yamanaka began his career in medical school in Kobe, Japan, but found that scientific discovery was more to his liking than orthopedic medicine. While working on liver cancer in transgenic mice as a post-doc in San Francisco, he discovered a gene, Nat1, which is important for early development and the differentiation of ES cells. That began his fascination with the genetic network of the pluripotent state of ES cells and how it is maintained. Returning to Japan, he undertook an in silico profiling of ES cells versus their differentiated progeny, which identified a set of highly enriched genes in ES cells. These included a number of genes encoding known and new transcription factors. One of these genes was Nanog, which both he and Austin Smith's lab showed to be a key player in the maintenance of the pluripotent state (Chambers et al., 2003; Mitsui et al., 2003) . Other genes included Oct4, Klf4, and Eras, all of which have been shown individually to be necessary for pluripotency but not sufficient on their own to induce pluripotency when ectopically expressed. What Yamanaka did then was simple in retrospect; he argued that to convert adult cells all the way back to pluripotency might require a combination of factors rather than a single master gene. He made a library of 24 ES cell-enriched factors in retroviral vectors and infected fibroblasts expressing a selectable marker gene under the control of one of the EScell-specific genes, Fbx15. Selecting these infected fibroblasts under ES cell culture conditions led to the appearance of colonies of ES-like cells over a period of time. Through a series of permutations and deletions of the 24 factors, he was able to bring the number of necessary genes down to the four socalled Yamanaka factors (Takahashi and Yamanaka, 2006) . Careful experimental design and a lot of hard work clearly paid off! Following his original experiments, there has been a huge explosion in iPS cell research, with Yamanaka still in the vanguard. Yamanaka has shown that iPS cells can be generated without the potentially oncogenic c-Myc , that they can be generated from There are two routes to generate personalized or patient-specific pluripotent stem cells. (Left) Nuclear transfer reprogramming involves injection of the nucleus of an adult cell into an enucleated oocyte. After a few days of development to the blastocyst stage, embryonic stem (ES) cells can be generated from any resulting viable blastocysts. (Right) During induced pluripotency, the adult cell is directly reprogrammed to pluripotency by transfection of a set of genes encoding key transcription factors, followed by careful selection and isolation of ES cell-like induced pluripotent stem (iPS) cells over a period of 2-3 weeks. Both approaches have proved feasible in mice. In humans, no nuclear transfer-derived stem cells have yet been reported; however, there are now numerous human iPS cells from normal and disease-bearing individuals available for study.
gastric epithelial cells and hepatocytes , and that it is possible to generate iPS cells at low efficiency by repeated transient transfection with a polycistronic plasmid containing all four factors . He has also become the voice for iPS cell research in Japan, now heading the Center for iPS Cell Research and Application (CiRA) at Kyoto University and also holding a cross-appointment at the Gladstone Institute.
Despite the huge popularity and profile of iPS cell research, there are still many uncertainties and unanswered questions before human iPS cells could be used for any direct therapeutic applications. Concern about possible insertional mutagenesis and oncogenic activation by retroviral integrations has led to a variety of efforts to achieve reprogramming without viral integration, including the use of transposon vectors that can be later excised from the genome, or replacement of the transgenes with small molecules or proteins. A more overriding concern, however, remains, and that is whether iPS cells may themselves be predisposed toward tumor formation. The inclusion of the protooncogene c-Myc in the original factor mix clearly enhanced the efficiency of reprogramming, but in the original mouse experiments, Yamanaka reported tumor formation in the chimeras generated from the iPS cells. Successful reprogramming can be achieved without c-Myc, but the efficiency is lowered. A series of recent reports from Yamanaka and others has shown that inactivation of the Ink4a/Arfp53 tumor suppressor pathway, even transiently, dramatically increases the efficiency of reprogramming. This pathway acts as a major antiproliferative and hence antitumorigenic pathway in mammalian cells, suggesting a clear relationship between induced pluripotency and tumorigenesis. These studies underscore how little we still really understand about the reprogramming process and certainly suggest that safe therapeutic use of these cells will require more knowledge than we have today.
However, the direct use of iPS cells for stem cell-based therapy is not the major reason for the excitement over this discovery. Generation of human iPS cells immediately opened up the possibility of efficiently making disease-specific stem cells from the cells of individuals with a wide range of disorders. Biobanking facilities for iPS cell lines are being established in a number of centers, and whole new programs of research into disease mechanisms, drug toxicology, and drug development are being fostered by the availability of these cells. The award of the Lasker prize to Yamanaka so soon after the discovery of iPS cells attests to the immense future potential of this approach to explore human biology and to treat human disease. But it also reflects the impact his discovery has had on the whole concept of the relative irreversibility of developmental pathways. If adult cells can be sent all the way back to pluripotency with just four transcription factors, why not redirect adult cells to therapeutically important cell types without going through the pluripotency step? And preferably do it in vivo to promote endogenous repair. A first step in this direction was the recent report of redirecting exocrine pancreas cells to endocrine cells by adenoviral transduction of three transcription factors in the living animal (Zhou et al., 2008) . It is a logical progression from Gurdon's first discovery-that an adult nucleus can retain totipotency after nuclear transfer-to the apparently unlimited future of directed reprogramming. Continued study of the mechanism of nuclear reprogramming by nuclear transfer should continue to inform and improve our ability to directly reprogram cell fate in adult cells.
Elements of Yamanaka's success echo those of John Gurdon's: focus on clear and simple questions and design simple and elegant experiments to address them. The Lasker award to both celebrates great science with great future impact on our understanding and treatment of human disease.
